Skip to content

Fanconi Anemia Complementation Group G C3469527

Published: July 22, 2026Updated: August 20, 2026

A genetic disorder involving the FANCG gene that disrupts DNA repair. Results in progressive bone marrow failure, birth defects, and greater cancer susceptibility. Treatment includes transfusions and transplant consideration.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D61.03
ICD-11
3A00.0
Body system
hematologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Pancytopenia

!

Bleeding tendency

!

Leukemia predisposition

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Short stature

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Hematopoietic Stem Cell Transplantation

Curative approach for bone marrow failure using chemotherapy and/or radiation followed by infusion of donor stem cells. This is the definitive treatment for severe aplastic anemia in Fanconi anemia patients.

surgical
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Androgen Therapy

Synthetic androgens such as oxymetholone may stimulate bone marrow production and improve blood counts. This serves as a bridge therapy while awaiting transplantation or for patients without a suitable donor.

medication

Additional treatment options

Comprehensive Cancer Surveillance Program

Regular screening including annual bone marrow exams, imaging studies, and tumor marker monitoring due to elevated solid tumor and hematologic malignancy risk in Fanconi anemia.

monitoring

Psychosocial Support Services

Counseling, support groups, and mental health services to address the chronic nature of the disease, treatment stress, and family adjustment challenges associated with Fanconi anemia.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Fanconi Anemia Complementation Group G C3469527?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Fanconi Anemia Complementation Group G C3469527. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy